MyHep All Tablets

Brand Name : MyHep All Tablets
Contents : Velpatasvir and Sofosbuvir
Marketed by : MyLan Pharmaceutical
Form : Tablets
Strength : Velpatasvir 100mg and Sofosbuvir 400 mg
Packing : Pack of 28 tablets

Myhep All – A single dose tablet :

(An Anti-viral medicine)

Myhep All hepatitis C viral medicine, hepatitis is a viral infection which leads to cause hepatic failure (liver damage)

Myhep All consisting of two most prominent antiviral components like sofosbuvir and Velpatasvir which exhibits effects against HCV virus infection by suppressing the non structural proteins NS5A & NS5B.

Myhep All is generally used alone or in some conditions like decompensated cirrhosis Myhep All should be combined with ribavirin

Myhep All is a single dose therapy, used as prescription medicine it is taken by the patients who are all having valid prescription with under the guidance of medical practitioner

MyHep All Used for

Myhep All is indicated in the condition;

Treatment of chronic hepatitis C viral infection induced by genotype I, II, III, IV, V or VI

Myhep All used for the patients having;

With cirrhosis or child Pugh A

With or without cirrhosis or child Pugh B or C (decompensated) cirrhosis

Myhep All dosage and administration;

Myhep All tablets are used in hepatitis C viral infection condition.

Myhep All tablets should be administered as a single dose

Myhep All should be taken with or without food. Food does not interfere with therapeutic effect of Myhep All

In decompensated cirrhosis condition, Myhep All should be combined with ribavirin and it must be taken with food The recommended dosage of Myhep All;

Myhep All tablets compose of 400mg of sofosbuvir and 100mg of Velpatasvir In chronic hepatitis C infection with genotype 1, 2, 3, 4, 5 & 6

One Myhep All tablet should be taken as a single dose with or without food

Therapy duration:

Patients with compensated cirrhosis (child Pugh A) or without cirrhosis:

Patients with compensated cirrhosis (child Pugh A) or without cirrhosis: One Myhep All tablet should be administered as once daily. It should be taken with food or without food

Decompensated cirrhosis:

One Myhep All tablet should be combined with ribavirin must be taken with food

In pediatric patients, Myhep All tablets safety and efficacy has not been established

Myhep All pharmacology

Myhep All exhibits its action by;

Myhep All has two components like sofosbuvir and Velpatasvir

Sofosbuvir has NS5B inhibitory activity, RNA polymerase inhibitor activity. This enzyme is important for viral growth. Inhibition of this enzyme causes suppression of viral activity. Velpatasvir has NS5A protein inhibitory effect, this protein is essential for viral multiplication. Velpatasvir exhibits its action by inhibiting the protein and causes viral termination The absorption of Myhep All tablet occurs rapidly. While taking Myhep All with any acid reducing agents causing depletion of effect of Velpatasvir. To avoid concomitant of Myhep All with antacids, H2 antagonist receptors & proton pump inhibitors

The peak concentration time of Myhep All;

Sofosbuvir occurs at within 0.5 to 1 hour

Velpatasvir occurs within 3 hours

Myhep All is bounded to human plasma protein like albumin, α glycoprotein Sofosbuvir binds with the range of 61 to 65% Velpatasvir binds with the range of >95% which has high binding capacity

Myhep All is metabolized hepatically Myhep All is a substrate of P-gp and breast cancer resistance protein Myhep All after metabolism, its metabolite eliminated through feces and urine; Velpatasvir is excreted as parent form The terminal half life period of Myhep All;

Sofosbuvir reaches 0.5 hour

Velpatasvir reaches 15 hours

Circulating metabolite GS-331007 reaches 25 hour

Myhep All drug interaction;;

Myhep all is a substrate of P-gp and breast cancer resistance protein In combination ofMyhep All with P-gp inducers like rifampicin, st. johns wort leads to causes reduction of plasma concentration of Myhep All which may reduce therapeutic effect of Myhep All Myhep All concurrently used with gastric pH regulating drugs like any antacids, proton pump inhibitors & H2 antagonist receptors causes depletion of effect of concentration of Velpatasvir Myhep All combination with amiodarone causes serious bradycardia symptomatically Concomitant of digoxin and Myhep All leads to produce elevating the serum concentration of digoxin

Myhep All combined with anti-convulsants like phenytoin, Phenobarbital or carbamazepine leads to depletes the serum concentration of Myhep All tablet Myhep All with anti-mycobacterials leads to decrease the serum concentration of Myhep All Myhep All combined with anti retroviral drugs causes depletion of serum concentration of Velpatasvir Myhep All combined with HMG CoA reductase agents like rosuvastatin, Atorvastatin causes increasing the concentration of these drugs

Myhep All contraindicated;

Myhep All tablets contraindicated to; Pregnant women,Myhep All combined with ribavirin causes fetal death Hypersensitivity reactions occurs due to the components ofMyhep All


Myhep All container should be kept at room temperature at below 30oC Container should be keep away from heat, moisture and light

Myhep All causes some side effects;

Some side effects occur during the therapy;

  • Headache
  • Diarrhea
  • Anemia
  • Nausea
  • InsomniaAsthenia
  • Depression
  • Increased creatinine kinase
  • Increased lipase
  • HBV reactivation
  • Bradycardia caused by concomitant with amiodarone


  • HBV reactivation occurs after the treatment, in patients who are having HBV/HCV co infection
  • Bradycardia occurs during concurrent use of amiodarone
  • Renal impairment
  • Hepatic impairment
  • In combination with ribavirin causes fetal harm
  • Concomitant use of Myhep All with P-gp inducers causes reduction in therapeutic effect of Myhep All

MyHep All Side Effects may include:

If patients fail to take the dose of Myhep All tablets, must consult physician and take the dose immediately as soon as possible; otherwise the missed dose should be skipped and follow the regular dosing schedule Do not take double dose If over dosage acquired in the patients, must investigate the critical signs and monitor the symptoms Hemodialysis is used to eradicate the component of Myhep All from the body, it is difficult to remove Velpatasvir because it is highly bound to human plasma protein .

MyHep All Tablets

Sofosbuvir and Velpatasvir Tablets 400mg/100mg

MyHep All »

MyLan Pharmaceutical Sofosbuvir and Velpatasvir is used to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. It may sometimes be used with another antiviral medication (ribavirin).…

Prescription :

myhepall is a fully licensed and regulated pharmacy, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.

myhepall will not dispense any prescription medication without a valid prescription from a licensed physician.

If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists

The drug information provided in the myhepall is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.

myhepall requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from myhepall.

myhepall is a Caregiver can order prescription medicines on your behalf.


This information should not be used to decide whether or not to take this Product or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this Product . It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this product. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this product.